TSP Capital Management Group LLC Has $16.20 Million Stock Position in MannKind Co. (NASDAQ:MNKD)

TSP Capital Management Group LLC boosted its holdings in shares of MannKind Co. (NASDAQ:MNKD) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,519,750 shares of the biopharmaceutical company’s stock after buying an additional 6,000 shares during the period. MannKind makes up about 5.5% of TSP Capital Management Group LLC’s holdings, making the stock its 3rd largest holding. TSP Capital Management Group LLC owned 0.91% of MannKind worth $16,202,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its stake in MannKind by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 58,475 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 5,585 shares during the period. New Wave Wealth Advisors LLC raised its position in MannKind by 78.6% during the fourth quarter. New Wave Wealth Advisors LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 22,000 shares in the last quarter. 180 Wealth Advisors LLC raised its position in MannKind by 1.0% during the fourth quarter. 180 Wealth Advisors LLC now owns 2,105,707 shares of the biopharmaceutical company’s stock valued at $13,540,000 after purchasing an additional 21,170 shares in the last quarter. Principal Financial Group Inc. raised its position in MannKind by 401.8% during the third quarter. Principal Financial Group Inc. now owns 168,518 shares of the biopharmaceutical company’s stock valued at $1,060,000 after purchasing an additional 134,937 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in MannKind by 3.0% during the third quarter. Franklin Resources Inc. now owns 160,016 shares of the biopharmaceutical company’s stock valued at $1,047,000 after purchasing an additional 4,603 shares in the last quarter. Institutional investors own 49.55% of the company’s stock.

Insider Activity at MannKind

In related news, Director Steven B. Binder sold 67,536 shares of the business’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $6.89, for a total transaction of $465,323.04. Following the transaction, the director now owns 1,075,026 shares in the company, valued at $7,406,929.14. The trade was a 5.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

MNKD has been the topic of a number of research reports. Wells Fargo & Company initiated coverage on MannKind in a research report on Friday, December 20th. They set an “overweight” rating and a $9.00 price target on the stock. Wedbush initiated coverage on MannKind in a research report on Monday. They set an “outperform” rating and a $11.00 price target on the stock. StockNews.com downgraded MannKind from a “buy” rating to a “hold” rating in a research report on Saturday, December 7th. Finally, Royal Bank of Canada upgraded MannKind from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $7.00 to $10.00 in a report on Thursday, December 19th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, MannKind has a consensus rating of “Buy” and an average target price of $9.21.

MannKind Trading Down 0.9 %

MNKD opened at $5.55 on Friday. The company has a market cap of $1.53 billion, a P/E ratio of 79.29 and a beta of 1.28. The business’s 50-day moving average price is $6.20 and its 200-day moving average price is $6.26. MannKind Co. has a 12 month low of $3.41 and a 12 month high of $7.63.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.